EFFICACY OF LONG-TERM TREATMENT WITH NIPRADILOL, A NITROESTER-CONTAINING BETA-BLOCKER, IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION

被引：7

作者：

HANEDA, T

OGAWA, Y

AKAISHI, T

TAKEDA, H

TANAZAWA, S

INOUE, H

OHKI, Y

KATO, J

MORIMOTO, H

KANAYA, K

ONODERA, S

KIKUCHI, K

机构：

[1] Asahikawa Medical College, Asahikawa

[2] Nayoro City Hospital, Nayoro

[3] National Hospital Nayoro, Nayoro

[4] Shibetsu Municipal Hospital, Shibetsu

[5] National Sanatorium Dohoku Hospital, Numata

[6] Asahikawa Kosei General Hospital, Asahikawa

[7] Fukagawa General Hospital, Fukagawa

[8] Numata Welfare Hospital, Numata

来源：

CLINICAL THERAPEUTICS | 1995年 / 17卷 / 04期

关键词：

D O I：

10.1016/0149-2918(95)80043-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effects of long-term treatment with nipradilol, a nitroester-containing beta-blocker, on casual and 24-hour blood pressures were studied in 70 patients with mild-to-moderate essential hypertension. Antihypertensive effects of nipradilol on casual blood pressure were observed in 68% of patients. Nipradilol reduced pulse rates, but no bradycardia was observed. The usefulness of nipradilol in the present study was 65%. The results of ambulatory blood pressure monitoring indicated that nipradilol reduced systolic blood pressure more than diastolic blood pressure, and reduced blood pressure during waking more than during sleep. These results suggest that nipradilol is a safe and useful long-term antihypertensive drug in both young and older patients with mild-to-moderate essential hypertension. When administered twice daily, nipradilol is effective throughout a 24-hour period.

引用

页码：667 / 679

页数：13

共 15 条

[1]

The Fifth Report of the Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure (JNC V), Archives of Internal Medicine, 153, pp. 154-183, (1993)

[2]

1993 Guidelines for the Management of Mild Hypertension Memorandum from a WHO/ISH meeting, Bull World Health Organ, 71, pp. 503-517, (1993)

[3]

Jydtin, Kusus, Daniel, Et al., Propranolol therapy in essential hypertension, American Heart Journal, 83, pp. 589-595, (1972)

[4]

Tarazi, Dustan, Beta-adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations, Am J Cardiol, 29, pp. 633-640, (1972)

[5]

Uchida, Nakamura, Shimizu, Et al., Vasoactive and beta-adrenoceptor blocking properties of 3,4-hydro-8(2-hydroxy-3-isopropylamino-propoxy)3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent, Arch Int Pharmacodyn Ther, 262, pp. 132-149, (1983)

[6]

Haneda, Ichihara, Onodera, Effects of nicorandil and nipradilol on ischemic myocardium in perfused rat heart, Eur J Pharmacol, 162, pp. 81-87, (1989)

[7]

Mancia, Ambulatory blood pressure monitoring: Research and clinical applications, J Hypertens, 8, pp. S1-S13, (1990)

[8]

White, Pickering, Morganroth, Et al., A multicenter evaluation of the A&D TM-2420 ambulatory blood pressure recorder, Am J Hypertens, 4, pp. 890-896, (1991)

[9]

Kaneko, Shionoiri, Limura, Et al., Hypotensive effect and safety of chronic administration of nipradilol (K-351) in essential hypertension, Ther Res, 5, pp. 135-154, (1986)

[10]

Rion, Waeber, Graf, Et al., Blood pressure response to antihypertensive therapy. Ambulatory versus office blood pressure readings, J Hypertens, 3, pp. 139-143, (1985)

← 1 2 →